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Abstract 
International clinical practice guidelines recommend 
early introduction and continued treatment with beta-
blockers for all patients without contraindications after 
STEMI. Although there seemed to be little question that 
patients with STEMI, regardless of revascularization 
strategy, derive substantial benefits from both long- and 
short-term beta-blockade, there has been a paucity of high 
quality evidence supporting this notion and the majority of 
data predate modern reperfusion therapy and current 
medical management strategies with statins and 
antiplatelet agents. Recently published data question this 
“one-size-fits-all” approach, showing that the use of beta-
blockers increased the risk of heart failure and cardiogenic 
shock with no mortality benefit. 
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List of Abbreviations 
AMI = acute myocardial infarction; EF = ejection fraction; ICD 
= implantable cardioverter defibrillator; HF = heart failure; LV 
= left ventric-le(-ular); MACE = major cardiovascular events; 
MI = myocardial infarction; NSTEMI = non-ST-elevation 
myocardial infarction; PCI = percutaneous coronary 
intervention; RAAS = renin-angiotensin aldosterone system; 
STEMI = ST-elevation myocardial infarction; VF = ventricular 
fibrillation 
 
Introduction 
Beta adrenergic receptor blockers have long been 
recommended for the treatment of all stages of ischemic 
heart disease, with the exception of Prinzmetal's 
vasospastic variant angina. Beta-Blockade is still regarded 
as standard therapy for effort angina, mixed effort and rest 
angina, and unstable angina. International clinical practice 
guidelines recommend beta-blocker therapy, both short- 
and long-term, to all acute coronary syndrome patients 
without contraindications, regardless of the 
revascularization strategy. However, much of the data to 
support their use predates reperfusion and contemporary 
medical therapy, while controversy also exists over the 
optimum timing of therapy initiation and discontinuation.  
 
Mechanisms of beta-blockers action 
Potentially beneficial effects of beta-blockers in 
patients with acute myocardial infarction (MI) include: 1,2  
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● Decreased oxygen demand due to the reductions in heart 
rate, blood pressure, and contractility, and the consequent 
relief of ischemic chest pain. 
● Decreased risk of ventricular fibrillation (VF), as 
suggested by experimental studies demonstrating an 
increase in the VF threshold and by clinical trials showing 
a relative risk reduction in sudden cardiac death.3-5 
● Decreased automaticity, increased electrophysiologic 
threshold for activation, and slowing of conduction. 
● Bradycardia, which prolongs diastole and therefore 
improves coronary diastolic perfusion and reduces after-
depolarizations and triggered activity. 
● Reduction in remodeling and improvement in left 
ventricular hemodynamic function, depending upon 
infarct size and the timing of treatment.6-8  
● Improved left ventricular diastolic function with a less 
restrictive filling pattern.9 
● Slowing of the yearly rate of progression of coronary 
atherosclerosis in patients with and without MI, as 
demonstrated by intravascular ultrasound evaluation of 
atheroma volume.10 
● Inhibition of platelet aggregation and thromboxane 
synthesis.11 
● One or more of the above mechanisms may contribute to 
a reduction in reperfusion injury. 
 
Clinical trials 
Studies prior to the use of thrombolysis have 
demonstrated both short- and long-term benefits, and a 
meta-analysis of these trials showed a 25% reduction in 
mortality at one year.12 Likewise, a similar analysis of the 
studies in patients treated with thrombolysis showed an 
overall 23% reduction in mortality.13 Early intravenous 
beta-blocker therapy also has been shown to improve both 
short-term and long-term outcome in the Thrombolysis in 
Myocardial Infarction II-B trial. 14 In the Carvedilol Post 
Infarction Survival Control in Left Ventricular 
Dysfunction (CAPRICORN) trial, high-risk STEMI 
patients with reduced left ventricular (LV) function who 
were treated with the beta-blocker carvedilol realized a 
reduction in mortality of 23% over a 2.5-year period.15 
The COMMIT (Clopidogrel and Metoprolol in 
Myocardial Infarction Trial) examined the effect of early 
intravenous then oral metoprolol in 45,852 patients with 
STEMI (93% with ST elevation or left bundle branch 
block), one-half of whom received fibrinolytic therapy. 
Patients who were going directly for percutaneous 
coronary intervention (PCI) were excluded. In this trial, 
patients were randomly assigned to placebo or to three 5 
mg intravenous boluses of metoprolol tartrate followed by 
oral metoprolol extended release (succinate) 200 mg/day 
for 30 days. The trial did find that beta-blockers resulted in 
less reinfarction and ventricular fibrillation at the expense 
of more cardiogenic shock, which is consistent with the 
benefit of this therapy in hemodynamically stable patients 
(who are not susceptible to shock).16  
The best evidence for early initiation of beta-blocker 
therapy in patients treated with current recommended 
therapies (e.g., statins, dual antiplatelet therapy) comes 
from the METOCARD-CNIC trial.17 In METOCARD-
CNIC, 270 patients with Killip class II or less anterior 
STEMI were randomly assigned to receive intravenous 
metoprolol (up to three 5 mg boluses of metoprolol tartrate 
given two minutes apart) or not before reperfusion and all 
patients received oral metoprolol within 24 hours. The 
primary end point of infarct size on magnetic resonance 
imaging performed 5-7 days was significantly smaller in 
the group that was treated early (25.6 vs 32.0 g; p = 0.012). 
In addition, left ventricular ejection fraction was higher in 
the treated group at 5-7 days and at 6 months (adjusted 
treatment difference 2.67%; p = 0.045 and 3.49%; p = 
0.025), and early metoprolol administration was associated 
with reduced incidence of severe LV systolic dysfunction, 
ICD indications and fewer heart failure admissions.18  
There was no difference in the safety end point. 
Limitations of the study include lack of a placebo control 
and exclusion of patients with inferior MI.  
The effect and optimal duration of oral beta-blocker 
therapy after primary PCI for patients with STEMI, has not 
been investigated in prospective, randomized studies and 
results from non-randomized studies are inconsistent. 
A retrospective review of observational data from 4 of 
the PAMI (Primary Angioplasty in Myocardial Infarction) 
studies, including 2,442 patients, found lower 6-month 
mortality associated with oral beta-blocker therapy at 
discharge (2.2% vs 6.6%, p > 0.0001; odds ratio [OR]: 
0.43, p= 0.0016).19 This study also showed that the 
associated lower mortality was confined to high-risk 
subgroups defined as those with an ejection fraction (EF) 
<50% (OR: 0.34, p > 0.0001) and those with multivessel 
coronary disease (OR: 0.26, p < 0.001). In a prospective 
observational study, OACIS (Osaka Acute Coronary 
Insufficiency Study), which included 5,628 patients with 
median follow-up of 1,430 days, the reduction in mortality 
associated with oral beta-blocker therapy was also seen in 
high-risk patients (hazard ratio [HR]: 0.60, p= 0.005) or 
those who received diuretic agents (HR: 0.60, p = 0.016).20  
For low-risk patients with a preserved EF who had 
STEMI treated with PCI, registry data from Japan 
including 12,824 patients with an EF>40% did not show a 
difference in 3-year mortality associated with oral beta-
blocker therapy at hospital discharge. 21 Similarly, the 
REACH (Reduction of Atherothrombosis for Continued 
Health) registry showed that the use of beta-blockers was 
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not associated with a lower risk of adverse events in stable 
patients with a previous history of MI. 22 In this registry 
14,000 patients with known prior MI were enrolled in 2003 
and 2004 and followed prospectively for up to four years. 
The primary outcome was a composite of cardiovascular 
death, nonfatal MI, or nonfatal stroke. Propensity score 
matching identified 3599 pairs of patients with and without 
beta blocker use. Aspirin and statin use (each) was 
approximately 75%. After a median follow-up of 44 
months, there was a trend toward a lower incidence of the 
primary outcome with beta-blocker therapy (16.9 vs 18.6 
percent, respectively; hazard ratio 0.90). However, little 
difference was seen in the event rates in the beta-blocker 
and no beta-blocker groups as early as two years. 
On the other hand, the results from a high-quality, large 
registry of 8,510 patients with STEMI treated with primary 
PCI focusing on outcomes associated with oral beta-
blocker therapy are different.23 The beta-blocker group had 
a significantly lower incidence of all-cause death (beta-
blocker group vs. no–beta-blocker group: 2.1% vs. 3.6%, 
unadjusted hazard ratio [HR]: 0.52, p < 0.001). The 
incidence of cardiac death was significantly lower in the 
beta-blocker group than in the no–beta-blocker group 
(1.1% vs. 2.4%, unadjusted HR: 0.41, p < 0.001), whereas 
both groups had comparable incidences of MI and any 
coronary revascularization. Although all-cause death or 
MI occurred less frequently in the beta-blocker group than 
in the no–beta-blocker group (3.1% vs 4.7%, unadjusted 
HR: 0.58, p < 0.001), there was no significant difference 
between the 2 groups in the rates of MACE. Interestingly, 
the association with better outcome of beta-blocker 
therapy in terms of all-cause death was consistent across 
various subgroups including patients with relatively low-
risk profile such as left ventricular ejection fraction >40% 
or single-vessel disease. Limitations of this (and other 
related observational studies), is the selection bias for the 
use of beta-blockers and the fact that beta-blocker therapy 
was defined as having a beta-blocker prescribed at the time 
of discharge, with little information about whether and 
how beta-blockers were continued. Thus, so far, most but 
not all observational data have suggested a benefit, varying 
with risk, with oral beta-blockers post-AMI. 
Recently, a large meta-analysis including 60 clinical 
trials with 102 003 patients, who were followed up for a 
mean of 10 months (range: in-hospital to 4 years) of 
follow-up, was published.24 Patients were stratified into 
two distinct eras: the reperfusion era, which included 12 
trials of 48 806 patients, treated in the modern era of 
thrombolysis and interventional procedures, and the pre-
reperfusion era, which included 48 studies with 31,479 
patients. In their analysis, the researchers observed a 
significant interaction between clinical outcomes and 
reperfusion era. In the acute MI trials, a significant 
interaction (P interaction=0.02) was noted with 
reperfusion status such that beta-blockers reduced 
mortality in the pre-reperfusion era [Incident Rate Ratio 
(IRR)=0.86] but not in the reperfusion era (IRR=0.98). In 
the pre-reperfusion era, beta-blockers were associated with 
reductions in cardiovascular mortality (IRR=0.87), MI 
(IRR=0.78), and angina (IRR=0.88), with no difference for 
sudden death (IRR=0.77), heart failure, cardiogenic shock 
or stroke (IRR=2.96). In the reperfusion era, beta-blockers 
were associated with reductions in myocardial infarction 
(IRR=0.72) and angina (IRR=0.80) at the expense of an 
increase in heart failure (IRR=1.10), cardiogenic shock 
(IRR=1.29) and drug discontinuation (IRR=1.64), with no 
impact on cardiovascular mortality (IRR=1.00) , sudden 
death (IRR=0.94) or stroke(IRR=1.09). Results in the post-
MI trials were largely similar. Regarding therapy duration, 
in the pre-reperfusion era, beta-blockers were associated 
with significant benefit at 30-days (for all-cause mortality, 
cardiovascular mortality and angina), between 30-days to 
1 year (for all-cause mortality, cardiovascular mortality, 
sudden death and MI) and even for events >1 year (for all-
cause mortality and sudden death). However, in the 
reperfusion era, beta- blockers were associated with no 
benefit at most time-points except MI and angina at 30-
days, a significant increase in heart failure, cardiogenic 
shock and drug discontinuation at 30-days, and an increase 
in heart failure and drug discontinuation between 30-days 
to 1 year. Researchers conclude that in patients undergoing 
contemporary treatment, data supports use of beta-
blockers short-term (30-days) to reduce recurrent MI and 
angina but this has to be weighed at the expense of increase 
in heart failure, cardiogenic shock and drug 
discontinuation with no mortality benefit and so clinical 
guidelines recommending the use of beta-blockers in post-
MI patients need to be "re-considered". 
 
Current Guidelines 
The American College of Cardiology Foundation/ 
American Heart Association (ACCF/AHA) STEMI 
guideline gives a class I (Level of Evidence B) 
recommendation for oral beta-blockers within the first 24 
hours in patients with myocardial infarction  and a class IIa 
(Level of evidence B) indication for intravenous beta-
blockers, for patients who are hypertensive or having 
ongoing ischemia. Patients with initial contraindications to 
the use of beta-blockers in the first 24 hours after STEMI 
should be reevaluated to determine their subsequent 
eligibility. Beta-blockers should be continued during and 
after hospitalization for all patients with STEMI and with 
no contraindications to their use. The long-term duration 
of routine beta-blocker therapy after uncomplicated MI in 
44 
 
patients without HF or hypertension has not been 
prospectively addressed. ACCF/AHA secondary 
prevention guidelines recommend a 3-year treatment 
course in this patient subset. Possible contra-indications to 
beta-blocker therapy include: signs of HF, evidence of a 
low output state, increased risk for cardiogenic shock 
(patients with age >70 years, systolic BP <120 mm Hg, 
presenting heart rate >110 bpm, or increased time since 
onset of symptoms of STEMI), PR interval more than 0.24 
seconds, second- or third-degree heart block, active 
asthma, or reactive airways disease.25, 26 European Society 
of Cardiology (ESC) ST-elevation myocardial infarction 
guidelines include similar recommendations.27 
 
Discussion 
Many of the key studies on which the recommendations 
of beta-blocker therapy are based, were performed in the 
era prior to routine administration of antiplatelet agents, 
thrombolysis or primary percutaneous coronary 
intervention, statins, and renin-angiotensin-aldosterone 
system (RAAS) blockers. There seemed to be little 
question that patients with STEMI, regardless of whether 
or not they have received thrombolysis or undergone PCI, 
derive substantial benefits from short- and long-term beta-
blocker therapy. The practice of prescribing beta-blockers 
is well accepted and widespread. However, accumulating 
data have called into question the role of beta-blockers in 
myocardial infarction. The rationale for beta-blockade, 
especially in revascularized patients without any 
significant residual coronary obstructions and 
uncomplicated hospital course is more or less unclear. 
Prompt reperfusion and contemporary medical and device 
therapies reduce the likelihood of extensive scar formation, 
modify the underlying substrate in patients with a 
myocardial infarction and reduce the risk of arrhythmic 
death, possibly lowering the effect of beta-blocker therapy. 
Conceivably, beta-blockers, due to their negative inotropic 
effects may reduce myocardial contractility, which in the 
setting of stunned myocardium during an myocardial 
infarction, could lead to heart failure and cardiogenic 
shock.24 On the other hand, data are more conclusive 
regarding patients  who develop extensive scar (patients 
with delayed presentation and large myocardial 
infarction), have reduced LV function or multi-vessel 
disease and therefore are prone to develop heart failure or 
ventricular arrhythmias. Beta-blockers will remain highly 
efficacious in preventing events, as has been shown in 
numerous heart failure trials and in preventing ventricular 
arrhythmias and sudden death.28, 29, 30, 31 Furthermore, most 
of the evidence supporting the benefit of beta- blockers has 
been obtained primarily from randomized trials that 
included predominantly patients with ST-elevation MI 
(STEMI). There have been no randomized trials 
specifically addressing the efficacy of these drugs in non-
ST elevation MI (NSTEMI) or unstable angina, however, 
there is no observational evidence to suggest different 
outcomes in patients with NSTEMI. Despite the favorable 
findings of the earlier studies and widespread use, 
compelling questions remain: whether low-risk patients 
(with normal ejection fraction and single vessel disease 
who have undergone successful angioplasty) receive any 
benefit from either long- or short-term beta-blocker 
therapy, what is the role of early intravenous or oral, pre-
procedural administration of beta blockers, do patients 
undergoing primary percutaneous intervention benefit 
from beta blocker therapy, when to start therapy and how 
long post myocardial infraction should beta-blockade be 
continued. 
 
Conclusions 
Beta-blockers are part of the quadruple therapy 
suggested by clinical practice guidelines post-MI (beta-
blockers, antiplatelet agents, statins, RAAS inhibitors). 
Beta-blockers act primarily by reducing myocardial 
oxygen demand, with negative chronotropic and inotropic 
effects that reduce heart rate, stroke volume, and blood 
pressure, increase coronary diastolic blood flow and 
myocardial perfusion, have antiarrhythmic effects 
showing a relative risk reduction in sudden cardiac death, 
reduce infract size and reverse adverse left ventricular 
remodeling. The overall evidence for the benefits of beta-
blocker therapy mainly in reducing morbidity and 
mortality are considered to be in favour of their use in this 
setting. Recent data have called into question the role of 
beta-blockers post-acute MI, demonstrating no mortality 
benefit, but reduced recurrent myocardial infraction and 
angina in the short term, at the expense of increased risk of 
heart failure and cardiogenic shock. Further data from a 
prospectively designed, randomized trial are needed to 
resolve this issue.  
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